Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment

Chugai has filed an application with Japan’s health ministry to approve Tecentriq as an adjuvant treatment for MSI-high colon cancer in adults and pediatric patients. The application is supported by the Phase III ATOMIC trial, which showed a three-year disease-free survival rate of 86.3% for the Tecentriq regimen compared to 76.2% for mFOLFOX6 alone.

Chugai filed with Japan’s health ministry for Tecentriq as adjuvant treatment for MSI-high colon cancer in adults, pediatric patients. * Application backed by Phase III ATOMIC trial in resected stage III dMMR colon cancer using Tecentriq with mFOLFOX6. * Three-year DFS reached 86.3% with Tecentriq regimen, 76.2% with mFOLFOX6; hazard ratio 0.50; p<0.001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here